Patents Assigned to Allogene Therapeutics, Inc.
  • Polynucleotides encoding rituximab-resistant chimeric antigen receptors
    Patent number: 11896617
    Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: February 13, 2024
    Assignee: ALLOGENE THERAPEUTICS, INC.
    Inventors: Thomas Charles Pertel, Barbra Johnson Sasu, Mark W. Leonard
  • Anti-TALEN antibodies and uses thereof
    Patent number: 11781248
    Abstract: The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: October 10, 2023
    Assignee: ALLOGENE THERAPEUTICS, INC.
    Inventors: Thomas Charles Pertel, Barbra Johnson Sasu
  • Antibodies against 4G7-derived chimeric antigen receptors
    Patent number: 11732041
    Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 22, 2023
    Assignee: ALLOGENE THERAPEUTICS, INC.
    Inventors: Thomas Charles Pertel, Barbra Johnson Sasu, Tao Sai
  • DLL3 targeting chimeric antigen receptors and binding agents
    Patent number: 11673953
    Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: June 13, 2023
    Assignees: ALLOGENE THERAPEUTICS, INC., PFIZER INC.
    Inventors: Yi Zhang, Thomas John Van Blarcom, Siler Panowski, Silvia K. Tacheva-Grigorova, Barbra Johnson Sasu
  • Modified caspase-9 polypeptides and methods of use thereof
    Patent number: 11326156
    Abstract: Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides. The disclosure further provides polynucleotides encoding these proteins, engineered host cells containing these polynucleotides and proteins, including host cells that co-express a chimeric antigen receptor, and methods of making and using the same.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 10, 2022
    Assignee: ALLOGENE THERAPEUTICS, INC.
    Inventors: Meritxell Galindo Casas, Thomas John Van Blarcom
  • INHIBITORY CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20220033462
    Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.
    Type: Application
    Filed: July 26, 2021
    Publication date: February 3, 2022
    Applicants: ALLOGENE THERAPEUTICS, INC., CELLECTIS
    Inventors: ARVIND RAJPAL, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
  • Inhibitory chimeric antigen receptors
    Patent number: 11072644
    Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: July 27, 2021
    Assignees: Allogene Therapeutics, Inc., Cellectis
    Inventors: Arvind Rajpal, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu